Price Target Update on Heat Biologics (NASDAQ:HTBX)

Heat Biologics (NASDAQ:HTBX) : Currently there are 2 street experts covering Heat Biologics (NASDAQ:HTBX) stock. The most bullish and bearish price target for the stock is $8 and $3 respectively for the short term. The average price target of all the analysts comes to $5.38. The estimated standard deviation from the target is $3.71.

Other Equity analysts have also commented on the company shares. Cantor Fitzgerald downgrades its view on Heat Biologics (NASDAQ:HTBX) according to the research report released by the firm to its investors. The shares have now been rated Speculative Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. The rating by the firm was issued on February 4, 2016.

Heat Biologics (NASDAQ:HTBX): stock turned positive on Thursday. Though the stock opened at $0.64, the bulls momentum made the stock top out at $0.83 level for the day. The stock recorded a low of $0.615 and closed the trading day at $0.8, in the green by 26.92%. The total traded volume for the day was 2,282,231. The stock had closed at $0.6303 in the previous days trading.

The company shares have dropped -90.83% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $7.00 and the one year low was seen on May 13, 2016. The 50-Day Moving Average price is $0.59 and the 200 Day Moving Average price is recorded at $1.34. On the companys insider trading activities, Kharitonov Michael, director of Heat Biologics, Inc., executed a transaction worth $675,000 on March 23, 2016. A total of 900,000 shares were purchased at an average price of $0.75. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Heat Biologics, Inc. is a biopharmaceutical company. The Company is engaged in developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. The Company has two product candidates, which include HS-110 and HS-410 that are being evaluated in Phase II clinical trials for non-small cell lung cancer and bladder cancer, respectively. Its ImPACT Immune Pan Antigen Cytotoxic Therapy has been designed to deliver live, genetically-modified, irradiated human cells, which secrete a spectrum of disease-associated antigens together with a potent immune response stimulator called gp96. In cancer patients its ImPACT therapy generates anti-cancer immune responses by mobilizing and activating cytotoxic killer T cells that target multiple cancer antigens, thus harnessing a patients own immune system to fight cancer. Its ImPACT therapeutic vaccines do not require custom manufacturing.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.